[Treatment outcomes in patients with unfavorable histologic type of endometrial carcinoma].
Five-year overall and recurrence-free survival was evaluated in 84 stage I endometrial cancer patients with such histological patterns as poorly differentiated endometrioid adenocarcinoma, clear-cell carcinoma, serous papillary cancer, poorly differentiated cancer and mixed-type carcinoma. Overall 5-year survival in the whole group was 60.1 +/- 5.9% while recurrence-free survival--52.1 +/- 5.9%, those rates for poorly differentiated endometrioid adenocarcinoma being 50.8 +/- 7.3% and 41.9 +/- 7.4%, respectively. Our data suggest that combination therapy is ineffective in the management of stage I endometrial carcinoma when histotype of tumor is unfavorable (overall 5-year survival - 56.51 +/- 7.8%; recurrence-free survival--49.7 +/- 7.9%).